Compare NWPX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | CRVS |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2016 |
| Metric | NWPX | CRVS |
|---|---|---|
| Price | $108.69 | $14.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $70.00 | $30.17 |
| AVG Volume (30 Days) | 127.9K | ★ 712.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.71 | ★ 48.04 |
| EPS | ★ 2.69 | N/A |
| Revenue | ★ $526,003,000.00 | N/A |
| Revenue This Year | $6.98 | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $40.55 | ★ N/A |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $49.45 | $5.60 |
| 52 Week High | $152.03 | $26.95 |
| Indicator | NWPX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 48.10 |
| Support Level | $106.57 | $12.76 |
| Resistance Level | $114.27 | $16.66 |
| Average True Range (ATR) | 3.56 | 0.59 |
| MACD | 0.28 | -0.08 |
| Stochastic Oscillator | 21.21 | 22.89 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.